CRIS Pharma
C.RIS Pharma is a French Contract Research Organization based in Saint-Malo, specializing in preclinical development of new active molecules for human diseases, as well as in Agrofood and Cosmetic areas. With over 18 years of experience, they provide high-quality non-clinical research management, GLP-compliant studies, and develop customized models to meet specific research needs. Their mission is to support pharmaceutical, agrofood, and cosmetic industries through scientific expertise, innovative models, and strict adherence to quality and confidentiality standards.
Industries
Nr. of Employees
small (1-50)
CRIS Pharma
Parc Technopolitain Atalante, Allée Ephyra – 35400 SAINT-MALO
Services
Design and execution of in vitro and in vivo efficacy models for pharmaceutical, agrofood and cosmetic products including oncology, metabolic, inflammatory, infectious, neurodegenerative and renal disease models.
Full-range GLP toxicology programs including genetic toxicology, general toxicity (acute to chronic), reproductive and developmental toxicology, carcinogenicity, immunotoxicity and toxicokinetics.
Cell-based assays for cosmetic efficacy (anti-acne, antiaging, melanin synthesis, slimming, healing) and agrofood endpoints (ACE inhibition, bone density markers, antioxidative ORAC, stress-relief assays).
Custom surgical models to assess biomaterials and cell-based reconstructive therapies with outcome monitoring (MRI, histology, immunohistochemistry).
Assessment of regulatory requirements, preparation of scientific and regulatory dossiers, risk assessment and assistance with submissions to authorities.
Project coordination, regular reporting, monitoring of outsourced studies and client communication throughout non-clinical development programs.
Design and execution of in vitro and in vivo efficacy models for pharmaceutical, agrofood and cosmetic products including oncology, metabolic, inflammatory, infectious, neurodegenerative and renal disease models.
Full-range GLP toxicology programs including genetic toxicology, general toxicity (acute to chronic), reproductive and developmental toxicology, carcinogenicity, immunotoxicity and toxicokinetics.
Cell-based assays for cosmetic efficacy (anti-acne, antiaging, melanin synthesis, slimming, healing) and agrofood endpoints (ACE inhibition, bone density markers, antioxidative ORAC, stress-relief assays).
Custom surgical models to assess biomaterials and cell-based reconstructive therapies with outcome monitoring (MRI, histology, immunohistochemistry).
Assessment of regulatory requirements, preparation of scientific and regulatory dossiers, risk assessment and assistance with submissions to authorities.
Project coordination, regular reporting, monitoring of outsourced studies and client communication throughout non-clinical development programs.
Expertise Areas
- Preclinical toxicology
- In vitro and in vivo efficacy model development
- Genetic toxicology
- Safety pharmacology and local tolerance testing
Key Technologies
- In vitro cell-based assays
- In vivo disease models
- Transgenic animal models
- Xenograft and syngeneic tumor models
News & Updates
C.RIS Pharma is a partner in the PKD-STOP project, developing a transgenic model of polycystic kidney disease, funded by Europe and Région Bretagne.
C.RIS Pharma is developing an in vitro cell model to evaluate anti-stress active drugs, supported by European and regional grants.
C.RIS Pharma is a partner in the PKD-STOP project, developing a transgenic model of polycystic kidney disease, funded by Europe and Région Bretagne.
C.RIS Pharma is developing an in vitro cell model to evaluate anti-stress active drugs, supported by European and regional grants.